GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verseon Corp (LSE:VERS) » Definitions » Change In Working Capital

Verseon (LSE:VERS) Change In Working Capital : £1.10 Mil (TTM As of Jun. 2019)


View and export this data going back to 2015. Start your Free Trial

What is Verseon Change In Working Capital?

Verseon's change in working capital for the quarter that ended in Jun. 2019 was £0.89 Mil.

Verseon's change in working capital for the fiscal year that ended in Dec. 2018 was £0.99 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).


Verseon Change In Working Capital Historical Data

The historical data trend for Verseon's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verseon Change In Working Capital Chart

Verseon Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Change In Working Capital
Get a 7-Day Free Trial 0.26 -0.79 -0.03 0.42 0.99

Verseon Semi-Annual Data
Dec11 Dec12 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19
Change In Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.43 0.83 0.75 0.20 0.89

Verseon Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Jun. 2019 adds up the semi-annually data reported by the company within the most recent 12 months, which was £1.10 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows Fiscal Years EndedJanuary 31,(Amounts in millions)
Cash flows from operating activities: 2014 2013 2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net (566) (614) (796)
Inventories (1,667) (2,759) (3,727)
Accounts payable 531 1,061 2,687
Accrued liabilities 103 271 (935)
Accrued income taxes (1,224) 981 994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Verseon Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Verseon's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Verseon (LSE:VERS) Business Description

Industry
Traded in Other Exchanges
N/A
Address
47071 Bayside Parkway, Fremont, CA, USA, 94538
Verseon Corp is a part of the healthcare sector in the United States. It is a technology-based pharmaceutical company with a computer-driven drug discovery platform. The company designs novel drug candidates that are unlikely to be found using conventional methods. It is also engaged in drug discovery programs such as the diabetic macular edema product candidates, which treat the diseases by controlled disruption of the kallikrein kinin cascade.

Verseon (LSE:VERS) Headlines